Inhaled and intranasal ciclesonide for the treatment of covid-19 in adult outpatients: CONTAIN phase II randomised controlled trial

Nicole Ezer(McGill University Health Centre), Emily G. McDonald(McGill University Health Centre), Nick Daneman(University of Toronto), James G. Martin(McGill University Health Centre), Benjamin M. Smith(McGill University Health Centre), Charlotte Besson(McGill University Health Centre), Todd C. Lee(McGill University Health Centre), Susan J. Bartlett(McGill University), Louisa Y Smyth, Sara Belga(University of British Columbia), Andrea Benedetti(McGill University), Shay-Anne Daniels(University of British Columbia), Kristen Moran, Adrienne K. Chan(Sunnybrook Health Science Centre)
BMJ
November 2, 2021
10.1136/bmj-2021-068060
Cited by 74

Related Papers

A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19
|New England Journal of Medicine|2020|1.4k
Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With <i>E coli</i> or <i>Klebsiella pneumoniae</i> Bloodstream Infection and Ceftriaxone Resistance
|JAMA|2018|761
Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis
|The Lancet|2018|639
Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19
|Annals of Internal Medicine|2020|548
Association Between Long-term Exposure to Ambient Air Pollution and Change in Quantitatively Assessed Emphysema and Lung Function
|JAMA|2019|396